Technology
PhaseRx is developing novel polymeric vehicles for the delivery of macromolecular therapeutics, including siRNA. The Company’s proprietary technology is a new type of synthetic, multi-functional polymer exclusively licensed from the University of Washington. The Company believes the favorable properties of these vehicles are that they:
- Mediate intracellular delivery
- Can be targeted to specific cells
- Are pharmaceutically developable
The polymers come from the laboratories of Patrick Stayton and Allan Hoffman at the University of Washington, which have world-class expertise in fine-tuning the polymers to meet intracellular and in vivo delivery needs.